Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors need to pay close attention to Johnson & Johnson (JNJ) stock based on the movements in the options market lately.

Implied Volatility Surging for Johnson & Johnson (JNJ) Stock Options

Lockheed Martin

Mastercard

Pfizer

Procter & Gamble

PayPal

Visa

These seven companies either have no exposure to inflation or have strong branding and customer loyalty, enabling them to pass higher costs. The post 7 Stocks to Buy for Their Resistance to the 6.2% Monthly Inflation appeared first on InvestorPlace.

7 Stocks to Buy for Their Resistance to the 6.2% Monthly Inflation

Apple

AbbVie

Chevron

McDonald's

Exxon Mobil

Buy these dividend stocks and forget them for 10 years, you will win big and should have little to worry about in the interim. The post 7 Dividend Stocks to Buy for 2022 and Hold Forever appeared first on InvestorPlace.

7 Dividend Stocks to Buy for 2022 and Hold Forever

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Johnson & Johnson (JNJ) Down 0.3% Since Last Earnings Report: Can It Rebound?

Bristol-Myers

Kraft Heinz

Coca-Cola

Mondelez

Royalty Pharma

Sirius XM Holdings Inc

STORE Capital

U.S. Bancorp

Verizon

This Buffett holdings list from Kiplinger first appeared 9/16/21 online. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 11/16/21 YCharts data. 28 of 43 current Berkshire Hathaway-owned stocks pay dividends. As of 11/16/21 the top-ten ranged 2.36%-4.92% by annual yield and ranged 18.73%-87.33% per broker-estimated price-target-upsides.

3 Ideal Dogs Delight Buffett's November Dividend Holdings

We view Johnson & Johnson's capital appreciation and dividend growth upside potential quite favorably.

Johnson & Johnson Is A Stellar Company With Ample Upside

Johnson & Johnson expects to file for approval of 14 new drugs by 2025, and has projected average peak sales of $4 billion a year for each, a top J&J scientist said ahead of a strategy review of the company's pharmaceuticals unit on Thursday.

J&J sees potential for 14 new multibillion-dollar drugs by 2025

Emerson Electric

PepsiCo

Target

6 years ago, I created a list of 5 stocks that I would always buy. The list was made with a long-term mindset, one that will survive multiple economic cycles and different administrations.

Bert's 5 Stocks To Always Buy... 6 Years Later

General Electric

Are you one of the many Americans invested in GE or Johnson & Johnson? Here's what you need to know about their upcoming moves, according to experts.

Your questions about the GE and Johnson & Johnson company breakups, answered

Past spinoffs by other companies could bode well overall for J&J shareholders.

Will Investors Win With Johnson & Johnson's Planned Spinoff? Here's What History Shows

J & J Snack Foods

J&J Snack Foods Corp. (JJSF) CEO Dan Fachner on Q4 2021 Results - Earnings Call Transcript

As iconic American corporations including GE and Johnson & Johnson pursue breakup plans, there are reasons this market may push more big names to be smaller.

Why more iconic companies like GE and J&J may be about to get smaller

Johnson & Johnson recently announced its plans to spin-off its Consumer Health business into a separate listed company. The Consumer Healthcare business garnered $14.0 billon of sales in 2020, while the rest of J&J revenues were $68.5 billion.

Will Johnson & Johnson Stock See Higher Levels After Its Split Announcement?

Novartis

S&P 500 investors can expect an average annual return of 7%, with upside potential based on the speed of technological innovation, according to DataTek Research.

Pfizer, J&J and Novartis Capture Top 3 Spots in Innovation Index

J&J (JNJ) is set to divide itself into two publicly traded companies. One will be its consumer products, while the other will comprise its pharmaceuticals and medical devices segments.

J&J (JNJ) to Separate Consumer Unit Into New Company, Stock Up

The world's largest drugmaker is splitting in two, but what does that mean for shareholders?

Should You Buy Johnson & Johnson Before It Splits?

And then there were two — or soon, there will be. Healthcare giant Johnson & Johnson's announcement last week that it would split its operations into two entities — one focusing on pharma/medical devices and one focusing on consumer products — represents a strategic nod to the fact that the direct-to-consumer (D2C) market is a […]

Johnson & Johnson Spinoff Plans Point to Rise of Direct to Consumer Commerce

Archer-Daniels-Midland Company

Aflac

Hershey

Main Street Capital

Microsoft

NextEra Energy

Raytheon Technologies

STAG Industrial

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: November 16-29, 2021

Alibaba

Merck

Royal Dutch Shell's pension fund exited an investment in Alibaba, and slashed positions in Pfizer, Johnson & Johnson, and Merck in the third quarter.

Shell's Pension Dropped Alibaba and Sold Big Pharma Stocks

Johnson & Johnson (NYSE: JNJ) announced its intent to separate the company's Consumer Health business, creating a new publicly traded company. These are the details.

Johnson & Johnson (JNJ) Splitting Into Two Publicly Traded Companies

On Friday, Johnson & Johnson (NYSE:JNJ) shares edged higher 1.44% amid reports the healthcare company plans to split into two. According to Wall Street Journal, JNJ wants to separate its drugs and medical devices business from the consumer products group, forming two publicly listed companies.

Johnson & Johnson stock forecast amid reports it plans to split into two

Johnson & Johnson is the latest in a line of mega-cap household names that have split their businesses in the name of focusing on growth

News for Johnson & Johnson Stock (JNJ)